Argenica (ASX:AGN) share price leapt 12% on US patent news today

This biotechnology company has released positive patent news.

four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Argenica Therapeutics Ltd (ASX: AGN) share price was rocketing today after the company released positive news on a US patent.

The biotechnology company's shares were up 12.36% at the close, trading at 75 cents.

Argenica is working on new therapeutics to protect the brain after a patient suffers a stroke and other brain injuries.

Why is the Argenica share price up today?

Investors appeared to welcome news the company will be granted a US patent for its lead drug candidate ARG-007.

Argenica said this meant it would be able to use ARG-007 to treat people with stroke, traumatic brain injury and hypoxic-ischaemic encephalopathy (HIE). HIE is a condition that arises from not having enough oxygen or blood flow to the brain.

Argenica now plans to spearhead the drug's commercialisation in the lucrative United States market.

The company advised it was given official "notice of allowance" for the patent, with the patent being formally granted within months.

The patent claim also covers the drug's use for other diseases including multiple sclerosis, Parkinson's disease, Huntington's disease and epilepsy.

Comment from management

Argenica CEO Dr Liz Dallimore welcomed the announcement, saying:

The granting of this patent will strengthen our ability to enter into commercial negotiations with US pharmaceutical companies in the future.

The allowance of the claims in Argenica's US patent are essential to potentially commercialising ARG-007 in our lead applications of stroke, TBI and HIE in the US.

Argenica Therapeutics share price snapshot

The Argenica share price has shot up in 2021, up 275%. The company listed on the ASX in June.

Over the past month, Argenica shares are up 50%. The company has a market capitalisation of about $35 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »